Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation - Wikidata - awgldk - TriplyDB

Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation

Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation

http://www.wikidata.org/entity/Q35820367

about

Targeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinib The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2.Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia.Targeting B Cell Signaling in Chronic Lymphocytic Leukemia.Chronic lymphocytic leukemia (CLL)-Then and now.Small Molecule Inhibitors in Chronic Lymphocytic Lymphoma and B Cell Non-Hodgkin Lymphoma.The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma.The role of Bruton's tyrosine kinase in autoimmunity and implications for therapy.BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.Clinical Implications of Novel Genomic Discoveries in Chronic Lymphocytic Leukemia.The molecular pathogenesis of chronic lymphocytic leukaemia.Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant.Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia.How I manage ibrutinib-refractory chronic lymphocytic leukemia.Mechanisms of Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia.Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia.BCR and chemokine responses upon anti-IgM and anti-IgD stimulation in chronic lymphocytic leukaemia.The Phospholipase Cγ2 Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein.The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia.Recent therapeutic advances in chronic lymphocytic leukemia.Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.Targeting BTK through microRNA in chronic lymphocytic leukemia.Clonal evolution in leukemia.Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy.HSP90 stabilizes B-cell receptor kinases in a multi-client interactome: PU-H71 induces CLL apoptosis in a cytoprotective microenvironment.PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment.A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era.Loss of TNFAIP3 enhances MYD88-driven signaling in non-Hodgkin lymphoma Functional characterization of phospholipase C-γ mutant protein causing both somatic ibrutinib resistance and a germline monogenic autoinflammatory disorder

P2860

Q26744277-6EAEF667-C13B-464C-BEFA-23963AF26975 Q26775506-186AEC0A-9EA5-4E5E-962F-EA728CDDCC54 Q30252869-743C583B-547D-4A97-B9A9-C29CFCBBC1CE Q36274292-AFAF5A3A-796F-43D3-BBDD-3E2177F8C7EF Q36413780-D870AE3D-3000-4414-A711-2F30CABABE67 Q37688589-E907F96D-CABD-47F2-8EA9-1B46E058FBD0 Q38654101-F911C7C6-C478-427A-8105-13B2AEF09B43 Q38675358-C8F176A3-4811-4EE0-9B79-AC00095A8CB5 Q38691282-C8D970CB-8DA9-4618-A744-A69BD94F00D4 Q38728157-6FE88E82-C07F-42D1-898D-EA62140CAAF5 Q38728631-12E6F619-4A74-4610-A30E-CDD332A6D53C Q38729031-1876B8C4-5C9F-40EA-B5B9-BC62C28534B0 Q38744632-182FD3F4-74E2-4E6E-81B3-2820F3846817 Q38748645-B15E125D-6876-452F-B132-31C90C76232D Q38765458-2F1596BD-C6F7-4DCF-BB2E-3375A2C38932 Q38818283-A46BCB6D-A054-4480-88E2-EAA95AC9E069 Q39016282-2EF6D178-75DF-4E42-B2BA-2F222CE97407 Q39169789-103132DC-6E44-45A9-B225-6DF0B7C409F1 Q40397638-79ED6B30-45FD-4D80-B3F9-DAADE15FC985 Q40469303-19A7A425-1F94-4826-B9BA-A3A1CB35B2EA Q42383180-E2A926E2-ED8F-4BBC-B2E6-EBB7B7B0B757 Q43090573-3435E575-523D-4EE7-8FA6-A676A3F7FAE0 Q46318389-37841367-0C04-4621-A4AF-0F199254FC07 Q47300370-47CE1D8B-DEE4-4941-BE79-EE202F0ADF8D Q48307279-F7713394-57F2-456F-AB02-2431477B2E50 Q48618984-3D31F3A1-BF09-488E-BC6C-AAE20040E5C7 Q48967836-E5D61D0A-D5C6-4D50-9112-0E6F398FC6F1 Q49557852-1DB02E58-6DC4-4C5E-A92E-2E0B3917964F Q50110556-33EA0C55-AF9B-4969-B20C-3E29698FC4F2 Q51173647-506CEE27-BFCB-462A-BE30-3C1F20DD8832 Q53745405-CC9512AB-51E0-428F-8B4F-B4F1BF2EA574 Q54979456-D0A330F8-CEBD-4347-B0F8-A0A75B1C1F69 Q57287569-14FE6B1F-75A2-40BD-9811-B8C46B17DDC2 Q57821054-1F897B0F-C9F4-41A6-872D-B4622FB27A6E

P2860

Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation

http://www.wikidata.org/entity/Q35820367

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Hypermorphic mutation of phosp ...... pon B-cell receptor activation

@ast

Hypermorphic mutation of phosp ...... pon B-cell receptor activation

@en

type

label

Hypermorphic mutation of phosp ...... pon B-cell receptor activation

@ast

Hypermorphic mutation of phosp ...... pon B-cell receptor activation

@en

prefLabel

Hypermorphic mutation of phosp ...... pon B-cell receptor activation

@ast

Hypermorphic mutation of phosp ...... pon B-cell receptor activation

@en

P1433

Q35820367-5479CFBE-A142-455A-872D-9D192CEA92C5

P1476

Q35820367-C91BF14E-D8EB-4BB0-A72C-20869FE07D40

P2093

Q35820367-090706AC-7EA2-4A96-A36A-AB0237B6E813

Q35820367-0921F027-5EAD-415A-83DD-23B187CB9975

Q35820367-0CF66533-3D57-4532-9DDE-C126A77E5724

Q35820367-33AEB512-5E23-4911-8292-82DA944E5CC8

Q35820367-358DE747-FA5A-44F9-B9E0-839ED54F4B96

Q35820367-606E5C2E-0BD3-4152-9BCF-8B3E8F9092D8

Q35820367-6D9C8196-1F7A-478D-8182-61C9F41E8B1D

Q35820367-77ADE357-33A1-43D6-993E-AD0B65358EE2

Q35820367-7E8CC4EB-79A7-40D6-BDF1-664963B853EE

Q35820367-8B0B8A3E-4ABC-4700-870C-F65A55BB5E52

P2860

Q35820367-04357C18-B4A1-4F63-BFCF-5C5D6A5E8FEB

Q35820367-0AA56D4D-3CE0-4C17-B4E9-C8699AD42352

Q35820367-0E97C3F6-3A51-4B71-8982-1BFFD4E30D12

Q35820367-28B64998-B4A7-4890-997A-DC9141D72B15

Q35820367-2EA5A36C-18C0-4699-9F3B-0593B807B99E

Q35820367-3729169E-5042-4709-A748-558127761C89

Q35820367-3FC7308E-C310-4258-BA47-A3840DC38A77

Q35820367-431C064C-52A3-4009-B83F-4270C68E348E

Q35820367-4863868E-4CEE-4A85-BB1D-88D218EB06E1

Q35820367-4B6B4412-D7CE-462F-BF88-08FD491D535D

P304

Q35820367-B0666951-29FF-4BFA-9B27-8FFC616649C7

P31

Q35820367-0796328E-01AC-4805-8681-29321284BC41

P356

Q35820367-B6439F36-664A-4D66-9133-6EEA5A938260

P407

Q35820367-1F0FE171-9C99-4ADC-9CBB-2575E1AB62D0

P433

Q35820367-387E2368-0B48-44C8-97DD-241175EB0304

P478

Q35820367-6AB07734-58F8-4848-8856-F429C2732953

P50

Q35820367-7025B58E-A1CF-4A15-BDCF-1459B76B8F69

Q35820367-E2C8EF5C-6911-4FFA-90E5-F36AD2581673

P577

Q35820367-84FA77F3-8D82-44CC-B156-37C7EA8B8F2C

P5875

Q35820367-F76552FF-2A1D-4C53-81D6-72CD7E5CF59C

P698

Q35820367-8A5A2E4A-6D07-4AEC-9063-DE8D9AE27A3B

P932

Q35820367-0594130B-9EF7-4E5E-AD17-E8BF64C776E9

P356

BLOOD-2015-02-626846

P1433

P1476

Hypermorphic mutation of phosp ...... pon B-cell receptor activation

@en

P2093

Amy J Johnson

http://www.w3.org/2001/XMLSchema#string

Amy Lehman

http://www.w3.org/2001/XMLSchema#string

Arletta Lozanski

http://www.w3.org/2001/XMLSchema#string

Gerard Lozanski

http://www.w3.org/2001/XMLSchema#string

Jason A Dubovsky

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Jones

http://www.w3.org/2001/XMLSchema#string

Jennifer A Woyach

http://www.w3.org/2001/XMLSchema#string

John C Byrd

http://www.w3.org/2001/XMLSchema#string

Joseph Flynn

http://www.w3.org/2001/XMLSchema#string

Kami Maddocks

http://www.w3.org/2001/XMLSchema#string

P2860

Regulation of the phospholipase C-gamma2 pathway in B cells

Activation of phospholipase Cgamma2 by tyrosine phosphorylation

Mapping of sites on the Src family protein tyrosine kinases p55blk, p59fyn, and p56lyn which interact with the effector molecules phospholipase C-gamma 2, microtubule-associated protein kinase, GTPase-activating protein, and phosphatidylinositol 3-k

The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib

BLNK required for coupling Syk to PLC gamma 2 and Rac1-JNK in B cells

Chronic lymphocytic leukemia

Four tyrosine residues in phospholipase C-gamma 2, identified as Btk-dependent phosphorylation sites, are required for B cell antigen receptor-coupled calcium signaling

Activation of phospholipase C-gamma by phosphatidylinositol 3,4,5-trisphosphate

BLNK: connecting Syk and Btk to calcium signals.

P304

61-68

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2015-02-626846

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

126

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-05-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

276360257

http://www.w3.org/2001/XMLSchema#string

P698

25972157

http://www.w3.org/2001/XMLSchema#string

P932

4492196

http://www.w3.org/2001/XMLSchema#string